423 completed, 150 terminated, 85 recruiting, 69 active not recruiting. 523 Phase 2, 354 Phase 1, 45 Phase 3, 39 Not applicable, 11 Early Phase 1.
Follow this drug Literature Review of fludarabine phosphate trials Research Report on fludarabine phosphate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome Busulfan, Melphalan, Fludarabine - Myelodysplastic Syndromes, Graft Vs Host Disease | Not applicable | Not yet recruiting | Guenther Koehne | 62 | 2027-01-01 | 2026-10-13 |
| CD34+ Transplants for Myeloid Malignancies Busulfan, Melphalan, Fludarabine - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute | Phase 2 | Not yet recruiting | Guenther Koehne | 50 | 2027-01-01 | 2026-10-13 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Fludarabine, Cytarabine, Idarubicin - Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 30 | 2026-11-30 | 2026-10-13 |
| Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-11-05 | 2026-10-08 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-26 | 2026-10-21 |
| Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) BMS-986353, Fludarabine Phosphate, Cyclophosphamide - Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia | Phase 2 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 52 | 2026-08-31 | 2026-07-09 |
| B7-H3.CD28Z.CART in Solid Tumors B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Pediatric Solid Tumor, Neuroblastoma | Phase 1 | Recruiting | Robbie Majzner | 40 | 2026-08-24 | 2026-09-03 |
| Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine - Gastric Cancer, Metastatic | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2026-08-11 | 2026-10-08 |
| Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma Cyclophosphamide, Fludarabine, LNK001 - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2026-07-02 | 2026-10-09 |
| Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies Fludarabine, TGFBR2 KO CAR27/IL-15 NK cells, Cyclophosphamide - Lymphoid, Hodgkin Lymphoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 60 | 2026-05-28 | 2026-09-08 |
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial") Cyclophosphamide, Fludarabine, Cetuximab - Colorectal Cancer, Peritoneal Metastases | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 28 | 2026-04-20 | 2026-10-05 |
| Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer ETB-DualNK-01, Fludarabine, Cyclophosphamide - Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma | Phase 1 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-11 |
| Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide - Unresectable Melanoma, Metastatic Cutaneous Melanoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-04 |
| Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma EBNK-1822H2 dual-target CLDN18.2/HER2 CAR-NK cells, Fludarabine, Cyclophosphamide - Recurrent or Metastatic Esophageal Adenocarcinoma, Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-06-03 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | Roswell Park Cancer Institute | 26 | 2026-02-02 | 2026-09-24 |
| Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) Dual-target CAR-NK cells (EB-DT-CAR-NK), Lymphodepleting chemotherapy, Supportive care - Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-02-02 | 2026-03-20 |
Showing 20 of 832. Sign in to see all of them.
Leukemia, Myeloid, Acute (230) · Leukemia, Lymphocytic, Chronic, B-Cell (214) · Leukemia (204) · Myelodysplastic Syndromes (188) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (175) · Lymphoma (148) · Lymphoma, Non-Hodgkin (143) · Multiple Myeloma (131) · Hodgkin Disease (123) · Lymphoma, Follicular (111) · Lymphoma, Mantle-Cell (108) · Lymphoma, Large B-Cell, Diffuse (96) · Lymphoma, B-Cell, Marginal Zone (89) · Myeloproliferative Disorders (87) · Congenital Abnormalities (86)
M.D. Anderson Cancer Center (112) · Fred Hutchinson Cancer Center (84) · National Cancer Institute (NCI) (74) · Masonic Cancer Center, University of Minnesota (52) · St. Jude Children's Research Hospital (19) · City of Hope Medical Center (18) · H. Lee Moffitt Cancer Center and Research Institute (14) · Baylor College of Medicine (13) · Alliance for Clinical Trials in Oncology (12) · Case Comprehensive Cancer Center (12) · UNC Lineberger Comprehensive Cancer Center (12) · University of California, San Francisco (12) · Chinese PLA General Hospital (11) · Memorial Sloan Kettering Cancer Center (11) · Roswell Park Cancer Institute (11)
United States (689) · China (37) · Italy (29) · Germany (28) · Canada (23) · Denmark (20) · United Kingdom (20) · France (17) · Australia (11) · Austria (10) · Russia (10) · Belgium (9) · Sweden (8) · South Korea (7) · Spain (7)
Brenda Sandmaier (16) · Steven A Rosenberg, M.D. (16) · Claudio G. Brunstein, MD, PhD (7) · James N Kochenderfer, M.D. (7) · Steven A. Rosenberg, MD, PhD (7) · Mary Horowitz, MD (6) · Richard E. Champlin, MD (6) · Brandon Triplett, MD (5) · David Maloney (5) · George Georges (5) · Steven Rosenberg, M.D. (5) · Uday Popat, MD (5) · Weidong Han, Ph.D (5) · Asad Bashey, MD, PhD (4)
PMID 32499241, PMID 34515338, PMID 22555974, PMID 21403127, PMID 22430088, PMID 35007144, PMID 36240296, PMID 16344317, PMID 18997171, PMID 19179301, PMID 20661232, PMID 23547837, PMID 23861247, PMID 24719405, PMID 24916506, PMID 25432172, PMID 27507877, PMID 28380315, PMID 30573690, PMID 32747469, PMID 34385708, PMID 34889384, PMID 12171484, PMID 12393429, PMID 14550808, PMID 15112270, PMID 15314059, PMID 15352988, PMID 15466923, PMID 16051743, PMID 16484584, PMID 16785067, PMID 17020988, PMID 17283363, PMID 17283364, PMID 17296974, PMID 17579184, PMID 17640728, PMID 17658394, PMID 18418404, PMID 18698002, PMID 19015393, PMID 19016733, PMID 19167681, PMID 19197729, PMID 19270751, PMID 19304957, PMID 19528536, PMID 19594547, PMID 19638218
P30CA015704 (53), P01CA018029 (19), U10CA031946 (12), P01CA078902 (9), P30CA033572 (9), U24CA076518 (7), P01CA044991 (6), P30CA006973 (6), P30CA016672 (6), P30CA043703 (6), U01HL069294 (6), P01CA015396 (4), U10CA180821 (4), U10CA180886 (4), P01HL036444 (3)